Understanding Implementation Challenges to Genetic Testing for Familial Hypercholesterolemia in the United States
Cardiovascular disease (CVD) is the leading cause of death in the United States (US), with familial hypercholesterolemia (FH) being a major inherited and genetic risk factor for premature CVD and atherosclerosis. Genetic testing has helped patients and providers confirm the presence of known pathoge...
Main Authors: | Rachele M. Hendricks-Sturrup, Christine Y. Lu |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-02-01
|
Series: | Journal of Personalized Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-4426/9/1/9 |
Similar Items
-
Barriers and Facilitators to Genetic Testing for Familial Hypercholesterolemia in the United States: A Review
by: Rachele M. Hendricks-Sturrup, et al.
Published: (2019-07-01) -
Integrating Patient-Reported Outcomes Into Clinical Genetic Testing for Familial Hypercholesterolemia
by: Rachele M. Hendricks-Sturrup, et al.
Published: (2021-10-01) -
Patient-Reported Outcomes following Genetic Testing for Familial Hypercholesterolemia, Breast and Ovarian Cancer Syndrome, and Lynch Syndrome: A Systematic Review
by: Rachele M. Hendricks-Sturrup, et al.
Published: (2021-08-01) -
A Global Review on the Utility of Genetic Testing for Familial Hypercholesterolemia
by: Rachele M. Hendricks-Sturrup, et al.
Published: (2020-04-01) -
Genetic testing for familial hypercholesterolemia—past, present, and future
by: Marta Futema, et al.
Published: (2021-01-01)